COVID-19 & Paxlovid Treatment: A Physician's Complete Guide

I still prescribe Paxlovid every week. That surprises many of my patients, who assume COVID-19 is "over." It isn't. The virus has become endemic — it circulates year-round, causes seasonal surges, and continues to hospitalize and kill people, particularly those over 65 and those with chronic conditions. What has changed is our ability to treat it. We now have an effective oral antiviral that, when started early enough, dramatically reduces the risk of a mild case becoming a catastrophic one.

Yet the majority of eligible patients never receive treatment. Some don't test. Some test too late. Some are told — incorrectly — that they don't qualify. And some are concerned about drug interactions or the "rebound" they've heard about and decide to ride it out. Every one of those scenarios represents a missed opportunity.

This guide is what I'd tell a family member who just tested positive for COVID-19. It covers who should get Paxlovid, when the treatment window closes, what drug interactions genuinely matter, what we've learned about rebound, and when mild symptoms signal something much more dangerous. It reflects the latest CDC treatment recommendations, FDA prescribing updates, and peer-reviewed research through early 2026.

Understanding COVID-19 in 2026

Six years into the pandemic, SARS-CoV-2 has settled into a pattern: continuous mutation, seasonal waves, and a population with highly variable immunity. The dominant variants in the United States as of early 2026 are XFG (approximately 29% of sequenced cases), NB.1.8.1 (21%), and XFG.2.5.1 (16%).^[7] All are Omicron-lineage subvariants. The original Omicron variant and its earlier sublineages (BA.2, BA.4, BA.5) are no longer circulating — they've been displaced by descendants that are better at evading existing immunity.

The symptom profile with current variants closely resembles previous Omicron waves: sore throat (often described as severe), congestion, cough, fatigue, headache, mild fever, and body aches. Loss of taste and smell — the hallmark of earlier pandemic strains — is now uncommon. For most healthy individuals, current variants do not appear more severe than their predecessors. But higher transmissibility means more total infections, which continues to put vulnerable populations at risk.

Who's Still at Risk

Roughly 75% of American adults have at least one condition that puts them at higher risk for severe COVID-19. That number isn't a scare tactic — it reflects how common risk factors actually are. They include:

• Age 50 and older (risk increases substantially after 65)
• Overweight or obesity (BMI ≥ 25)
• Diabetes (type 1 or type 2)
• Cardiovascular disease (heart failure, coronary artery disease, cardiomyopathies)
• Chronic lung disease (COPD, asthma, interstitial lung disease)
• Chronic kidney disease
• Immunosuppression (from medications, organ transplant, cancer treatment, or HIV)
• Mental health conditions (particularly those on certain psychiatric medications)
• Smoking (current or former)
• Physical, developmental, or intellectual disabilities

If you recognize yourself in that list — and statistically, most adults will — you should have a plan for treatment before you need it.

Paxlovid: What It Is and How It Works

Paxlovid is a combination of two medications packaged together: nirmatrelvir and ritonavir. Each dose consists of three pills — two nirmatrelvir tablets and one ritonavir tablet — taken together twice daily for 5 days.^[3]

Nirmatrelvir is the antiviral workhorse. It inhibits the SARS-CoV-2 main protease (Mpro), an enzyme the virus needs to process its polyproteins into functional components. Block Mpro, and the virus can no longer produce the proteins it needs to assemble new viral particles. The virus that's released from infected cells is essentially defective — it can't infect new cells, which halts the chain of replication.

Ritonavir has no direct antiviral activity against SARS-CoV-2. Its role is pharmacokinetic: it inhibits the CYP3A enzyme system in the liver, which is the primary pathway for breaking down nirmatrelvir. Without ritonavir, nirmatrelvir would be metabolized too quickly to maintain effective antiviral levels. Ritonavir essentially keeps nirmatrelvir in the bloodstream long enough to work. This "boosting" strategy has been used in HIV treatment for decades.

How Well Does It Work?

In the pivotal EPIC-HR clinical trial, Paxlovid reduced the risk of hospitalization and death by 89% in unvaccinated high-risk patients when started within 3 days of symptoms, and 87% when started within 5 days.^[1] Subsequent real-world studies during the Omicron era — including in vaccinated populations — confirmed meaningful benefit. A 2022 CDC real-world study showed a 51% reduction in 30-day hospitalization among treated adults, including those with prior vaccination or infection.^[3]

Pay attention to this: Paxlovid targets the viral main protease, which is highly conserved across SARS-CoV-2 variants. Unlike monoclonal antibodies (most of which lost efficacy against Omicron subvariants), Paxlovid's mechanism of action is less likely to be affected by spike protein mutations. It remains effective against all currently circulating variants.^[1]

Who Should Get Treated

Paxlovid is FDA-approved for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. It is also authorized under EUA for children ages 12–17 weighing at least 88 pounds (40 kg).^[1]

"High risk" is determined by the prescribing physician based on the patient's overall medical history. The CDC identifies the following as factors associated with increased risk for severe COVID-19:

• Age 50 years and older (especially ≥ 65)
• Obesity (BMI ≥ 30) or overweight (BMI ≥ 25)
• Diabetes (type 1 or type 2)
• Cardiovascular disease
• Chronic lung disease (COPD, moderate-to-severe asthma)
• Chronic kidney disease
• Immunocompromised state (from disease or medications)
• Pregnancy
• Smoking (current or former)
• Sickle cell disease
• Substance use disorders
• Mental health conditions

There are specific contraindications: Paxlovid should not be used in patients with severe kidney impairment (eGFR < 30 mL/min) unless on the new severe renal impairment dosing regimen, severe liver impairment (Child-Pugh Class C), or a history of serious hypersensitivity to nirmatrelvir or ritonavir. Dose reduction is required for moderate kidney impairment (eGFR 30–60 mL/min).^[1]

Decision Framework: Treat at Home, Get Paxlovid, or Go to the ER

Not every positive COVID-19 test requires Paxlovid, and not every case of COVID-19 can be safely managed at home. Here's the clinical framework I use:

The most common mistake I see is patients waiting too long to seek treatment. By day 6 or 7 of symptoms, Paxlovid is no longer indicated — and by that point, the damage from the inflammatory response may already be underway. If you have risk factors and test positive, contact your physician on day one.

Drug Interactions and Side Effects

It's the section that matters most for patient safety. Paxlovid's drug interaction profile is its most significant clinical limitation — and it stems almost entirely from ritonavir.

Ritonavir is a potent inhibitor of the CYP3A enzyme system. Any medication that is broken down by CYP3A will linger in the body at higher — sometimes dangerously higher — levels when taken alongside Paxlovid. The FDA prescribing information carries a boxed warning about this.^[2]

Statins (Cholesterol Medications)

Statins are among the most commonly prescribed medications in the United States, so this interaction comes up frequently. Paxlovid blocks the enzyme that metabolizes statins, leading to elevated statin levels and increased risk of muscle damage (myopathy) or, in rare cases, rhabdomyolysis — a serious condition where muscle tissue breaks down and can damage the kidneys.

• Lovastatin and simvastatin: Must be stopped 12 hours before starting Paxlovid and not restarted until 5 days after the last Paxlovid dose.^[2]
• Atorvastatin: Should be held during the 5-day Paxlovid course and restarted the day after completion.
• Rosuvastatin: May interact to a lesser degree but should still be held during treatment.

A brief pause in statin therapy — typically 10 days total — is clinically insignificant. Statins work over weeks and months; missing 10 days will not meaningfully affect your cardiovascular risk.

Blood Thinners (Anticoagulants and Antiplatelets)

This is a more complex interaction because the consequences of both too much and too little anticoagulation are serious.

• Warfarin (Coumadin): Ritonavir can alter warfarin metabolism unpredictably, potentially causing dangerously high or low INR levels. Close monitoring is required.
• Apixaban (Eliquis): Paxlovid significantly increases apixaban levels, raising bleeding risk. Dose reduction or temporary hold with physician guidance is essential.^[2]
• Rivaroxaban (Xarelto): Coadministration is generally avoided due to substantially increased drug levels and bleeding risk.
• Clopidogrel (Plavix): Ritonavir may actually decrease the effectiveness of clopidogrel by inhibiting its conversion to the active metabolite.

Immunosuppressants

For transplant patients and those on immunosuppressive therapy, the interaction with Paxlovid can be life-threatening. Calcineurin inhibitors (tacrolimus, cyclosporine) are the most commonly reported medications causing serious adverse reactions when combined with Paxlovid.^[2] These patients require specialist coordination — often involving their transplant team — to safely manage dosing during Paxlovid treatment.

Other Notable Interactions

• Calcium channel blockers (amlodipine, diltiazem, nifedipine): Increased levels; monitor for low blood pressure and excessive heart rate reduction.
• Certain anti-seizure medications (carbamazepine, phenytoin): These are CYP3A inducers — they may reduce Paxlovid effectiveness rather than increasing it.
• Erectile dysfunction medications (sildenafil, tadalafil): Significantly elevated levels; do not use during Paxlovid treatment.
• Certain psychiatric medications (quetiapine, midazolam): Contraindicated with ritonavir due to risk of excessive sedation.

Common Side Effects of Paxlovid

The most frequently reported side effect is dysgeusia — an altered or metallic taste in the mouth. It's unpleasant but harmless and resolves after treatment ends. Other common side effects include diarrhea, muscle aches, and elevated blood pressure. Serious adverse events are uncommon when drug interactions are properly managed.

Paxlovid Rebound: What We Know

Paxlovid rebound has received outsized attention relative to its clinical significance. Here's what the evidence actually shows.

What it is: A return of COVID-19 symptoms and/or a positive test result 2 to 8 days after completing the 5-day Paxlovid course, following initial improvement.

How common is it? Estimates vary widely — from less than 1% to over 30% — depending on how rebound is defined and measured. A key finding from clinical trials is that rebound occurs at similar rates in patients who received placebo, suggesting it may be a feature of COVID-19 itself rather than a Paxlovid-specific phenomenon.^[4]

Why it happens: A 2025 mathematical modeling study from Los Alamos National Laboratory provided a plausible explanation. When Paxlovid is given early, it effectively halts viral replication — but it also preserves uninfected target cells. When the drug clears the body after 5 days, residual infectious viral particles can infect those preserved cells before the adaptive immune response has fully developed. The study suggests that a 10-day course might reduce rebound risk, though this hasn't yet been tested in randomized clinical trials.^[4]

Is it dangerous? No. A phase 2 randomized trial published in 2025 found that retreatment with a second course of Paxlovid after rebound was safe but showed no clinical benefit — because the rebound itself was "transient, mild, and did not lead to severe COVID-19." None of the participants who experienced rebound were hospitalized or died.^[4]

What I tell my patients: Rebound is a possibility, not a reason to avoid treatment. The goal of Paxlovid is to prevent severe disease, hospitalization, and death — and it does that whether or not rebound occurs. If symptoms return after completing treatment, monitor them. If they're mild, they'll resolve. If they worsen or you develop warning signs (high fever, difficulty breathing), seek medical evaluation.

Prevention: Vaccines, Testing, and Common Sense

Updated Vaccine Guidance (2025–2026)

The CDC recommends the 2025–2026 COVID-19 vaccine for everyone ages 6 months and older, based on individual-based decision-making (shared clinical decision-making between patient and provider).^[5] The updated vaccine uses a monovalent JN.1-lineage composition (LP.8.1 strain) to better match currently circulating variants. Available formulations include Moderna (Spikevax and mNexspike), Pfizer-BioNTech (Comirnaty), and Novavax.

Vaccination is especially important if you are 65 or older, have high-risk conditions, or have never been vaccinated. Even for previously vaccinated or previously infected individuals, immunity wanes over time and variant evolution can reduce cross-protection.

When to Test

Test if you develop symptoms consistent with COVID-19, particularly during known surges or after exposure to a confirmed case. Rapid antigen tests are widely available. If your rapid test is negative but symptoms persist, consider retesting in 24–48 hours — false negatives are more common in the first 1–2 days of symptoms.

The reason to test promptly isn't just to know your diagnosis — it's to start the treatment clock. Every day of delay narrows the Paxlovid window.

Basic Prevention Measures

• Stay home when sick — this remains the single most effective way to prevent transmission.
• Good hand hygiene and respiratory etiquette (covering coughs and sneezes).
• Ventilation — opening windows or using air filtration in shared indoor spaces reduces airborne transmission.
• High-quality masks (N95, KN95) in high-risk settings or during surges, particularly for immunocompromised individuals.
• Pre-exposure prophylaxis — Pemgarda (pemivibart) is available for certain moderately or severely immunocompromised patients who may not respond adequately to vaccination.^[1]

Red Flags: When to Seek Emergency Care

COVID-19 has a well-documented pattern of biphasic illness: patients may feel they're improving around days 5–7, then deteriorate rapidly around days 7–10 as the inflammatory phase overtakes the viral replication phase. This is when pneumonia, cytokine storm, and respiratory failure can develop. If you're in the second week of illness and symptoms are worsening rather than improving, do not wait.

For patients who are managing COVID-19 at home, I recommend a pulse oximeter. These inexpensive devices clip onto your finger and measure blood oxygen levels. A consistent reading below 94% warrants medical evaluation even if you feel "okay" — silent hypoxia (low oxygen without proportional shortness of breath) was one of the most dangerous patterns we observed earlier in the pandemic, and it still occurs.

Frequently Asked Questions